SynapseBio uses Machine Learning
and EEG to Improve Detection and Treatment
of Dementia and Other Neurological and Psychiatric Disorders
SynapseBio is a venture backed Digital Health company founded within AlleyCorp focused on utilizing statistical and machine learning models to assess EEG and other biophysical data for the purpose of improving the detection and treatment of dementia and other Neurological and Psychiatric disorders.
Why It Matters
Why It Matters
Clinical trials in neurology and psychiatry are expensive, subjective, and among the very worst performers across indications
Proprietary machine learning algortihms reveal patterns in EEG that up until now have been difficult or impossible to identify
We use these patterns to create digital biomarkers for clinical trial
subject selection and treatment monitoring
What How We Do
Over the past several years, SynapseBio has developed and refined a domain specific process and algorithm trained to clean and standardize EEG data and generate ML features which has demonstrated efficacy in advanced disease detection across multiple Neurological and Psychiatric disorders
Clean
Validated algorithm that has been proven to provide a clear signal
Accurate and transparent
Generation of EEG features in a quantitative structure for ML analysis and proprietary ML algorithms generate signal precision
Repeatable
Coding of signal for repeatable digital biomarker use by payers / providers and pharma
Our Digital Biomarkers
SynapseBio is focusing first on 2 clinical trial use cases
Subject selection
Treatment monitoring
contact@synapsebioai.com
Phone
+1 (212) 634-4062